Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in <scp>SOD1</scp>‐related <scp>ALS</scp>: Treatment experience in clinical practice
Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in <scp>SOD1</scp>‐related <scp>ALS</scp>: Treatment experience in clinical practice is a paper indexed in PICO Portal from OpenAlex.
How many citations does Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in <scp>SOD1</scp>‐related <scp>ALS</scp>: Treatment experience in clinical practice have?
Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in <scp>SOD1</scp>‐related <scp>ALS</scp>: Treatment experience in clinical practice has 102 citations in the OpenAlex counts PICO Portal stores.
When was Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in <scp>SOD1</scp>‐related <scp>ALS</scp>: Treatment experience in clinical practice published?
Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in <scp>SOD1</scp>‐related <scp>ALS</scp>: Treatment experience in clinical practice has 2023 year in the PICO Portal index.
What is the open-access status of Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in <scp>SOD1</scp>‐related <scp>ALS</scp>: Treatment experience in clinical practice?
Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in <scp>SOD1</scp>‐related <scp>ALS</scp>: Treatment experience in clinical practice has bronze oa status in the PICO Portal index.
What is the DOI of Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in <scp>SOD1</scp>‐related <scp>ALS</scp>: Treatment experience in clinical practice?
The DOI for Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in <scp>SOD1</scp>‐related <scp>ALS</scp>: Treatment experience in clinical practice is on the source record.
What is the PMID of Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in <scp>SOD1</scp>‐related <scp>ALS</scp>: Treatment experience in clinical practice?
The PMID for Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in <scp>SOD1</scp>‐related <scp>ALS</scp>: Treatment experience in clinical practice is on the source record.
What is the OpenAlex record for Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in <scp>SOD1</scp>‐related <scp>ALS</scp>: Treatment experience in clinical practice?
The OpenAlex for Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in <scp>SOD1</scp>‐related <scp>ALS</scp>: Treatment experience in clinical practice is on the source record.